Prognosis and hormone receptor status in older and younger patients with advanced-stage papillary serous ovarian carcinoma

Gynecologic Oncology

Volumn 115, Issue 3, 2009, Pages 401-406

  Liu, Joyce F ^a   Hirsch, Michelle S ^b   Lee, Hang ^c   Matulonis, Ursula A ^a  

^a DANA FARBER CANCER INSTITUTE   (United States)

^b BRIGHAM AND WOMEN S HOSPITAL   (United States)

^c MASSACHUSETTS GENERAL HOSPITAL   (United States)

Author keywords

Age; Elderly; Hormone receptor; Ovarian cancer

Indexed keywords

ESTROGEN RECEPTOR; PLATINUM DERIVATIVE; PROGESTERONE RECEPTOR;

ADULT; AGE; AGED; ARTICLE; CANCER CHEMOTHERAPY; CANCER STAGING; CANCER SURVIVAL; CONTROLLED STUDY; HIGH DENSITY TISSUE MICROARRAY; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; MAJOR CLINICAL STUDY; MICROARRAY ANALYSIS; OVARY CARCINOMA; PRIORITY JOURNAL; PROGNOSIS;

AGED; CARCINOMA, PAPILLARY; CYSTADENOCARCINOMA, SEROUS; FEMALE; HUMANS; IMMUNOHISTOCHEMISTRY; KAPLAN-MEIER ESTIMATE; MIDDLE AGED; MULTIVARIATE ANALYSIS; OVARIAN NEOPLASMS; PROGNOSIS; PROPORTIONAL HAZARDS MODELS; RECEPTOR, ERBB-2; RECEPTORS, ESTROGEN; RECEPTORS, PROGESTERONE;

EID: 70350451938     PISSN: 00908258     EISSN: 10956859     Source Type: Journal    
DOI: 10.1016/j.ygyno.2009.08.023     Document Type: Article

References (28)

1. Jemal A., Siegel R., Ward E., Hao Y., Xu J., Murray T., et al. Cancer statistics, 2008. CA Cancer J. Clin. 58 2 (2008) 71-96
2. Yancik R. Ovarian cancer. Age contrasts in incidence, histology, disease stage at diagnosis, and mortality. Cancer 71 2 Suppl (1993) 517-523
3. Pignata S., and Vermorken J.B. Ovarian cancer in the elderly. Crit. Rev. Oncol. Hematol. 49 1 (2004) 77-86
4. Alberts D.S., Dahlberg S., Green S.J., Garcia D., Hannigan E.V., O'Toole R., et al. Analysis of patient age as an independent prognostic factor for survival in a phase III study of cisplatin-cyclophosphamide versus carboplatin-cyclophosphamide in stages III (suboptimal) and IV ovarian cancer. A Southwest Oncology Group study. Cancer 71 2 Suppl (1993) 618-627
5. Markman M., Lewis Jr. J.L., Saigo P., Hakes T., Rubin S., Jones W., et al. Impact of age on survival of patients with ovarian cancer. Gynecol. Oncol. 49 2 (1993) 236-239
6. Thigpen T., Brady M.F., Omura G.A., Creasman W.T., McGuire W.P., Hoskins W.J., et al. Age as a prognostic factor in ovarian carcinoma. The Gynecologic Oncology Group experience. Cancer 71 2 Suppl (1993) 606-614
7. Hempling R.E., Piver M.S., Eltabbakh G.H., and Recio F.O. Progesterone receptor status is a significant prognostic variable of progression-free survival in advanced epithelial ovarian cancer. Am. J. Clin. Oncol. 21 5 (1998) 447-451
8. Ho S.M. Estrogen, progesterone and epithelial ovarian cancer. Reprod. Biol. Endocrinol. 1 (2003) 73
9. Munstedt K., Steen J., Knauf A.G., Buch T., von Georgi R., and Franke F.E. Steroid hormone receptors and long term survival in invasive ovarian cancer. Cancer 89 8 (2000) 1783-1791
10. Garcia-Velasco A., Mendiola C., Sanchez-Munoz A., Ballestin C., Colomer R., and Cortes-Funes H. Prognostic value of hormonal receptors, p53, ki67 and HER2/neu expression in epithelial ovarian carcinoma. Clin. Transl. Oncol. 10 6 (2008) 367-371
11. Pignata S., Ferrandina G., Scarfone G., Scollo P., Odicino F., Cormio G., et al. Poor outcome of elderly patients with platinum-sensitive recurrent ovarian cancer: results from the SOCRATES retrospective study. Crit. Rev. Oncol. Hematol. (2009)
12. Matulonis U.A., Krag K.J., Krasner C.N., Atkinson T., Horowitz N.S., Lee H., et al. Phase II prospective study of paclitaxel and carboplatin in older patients with newly diagnosed Mullerian tumors. Gynecol. Oncol. 112 2 (2009) 394-399
13. Newcomb P.A., and Carbone P.P. Cancer treatment and age: patient perspectives. J. Natl. Cancer Inst. 85 19 (1993) 1580-1584
14. Ries L.A. Ovarian cancer. Survival and treatment differences by age. Cancer 71 2 Suppl (1993) 524-529
15. Eisenhauer E.L., Tew W.P., Levine D.A., Lichtman S.M., Brown C.L., Aghajanian C., et al. Response and outcomes in elderly patients with stages IIIC-IV ovarian cancer receiving platinum-taxane chemotherapy. Gynecol. Oncol. 106 2 (2007) 381-387
16. Giede K.C., Kieser K., Dodge J., and Rosen B. Who should operate on patients with ovarian cancer? An evidence-based review. Gynecol. Oncol. 99 2 (2005) 447-461
17. Earle C.C., Schrag D., Neville B.A., Yabroff K.R., Topor M., Fahey A., et al. Effect of surgeon specialty on processes of care and outcomes for ovarian cancer patients. J. Natl. Cancer Inst. 98 3 (2006) 172-180
18. Guidelines for referral to a gynecologic oncologist: rationale and benefits. The Society of Gynecologic Oncologists. Gynecol. Oncol. 78 3 Pt 2 (2000) S1-S13
19. Wright J.D., Herzog T.J., and Powell M.A. Morbidity of cytoreductive surgery in the elderly. Am. J. Obstet. Gynecol. 190 5 (2004) 1398-1400
20. Slamon D.J., Godolphin W., Jones L.A., Holt J.A., Wong S.G., Keith D.E., et al. Studies of the HER-2/neu proto-oncogene in human breast and ovarian cancer. Science 244 4905 (1989) 707-712
21. Bookman M.A., Darcy K.M., Clarke-Pearson D., Boothby R.A., and Horowitz I.R. Evaluation of monoclonal humanized anti-HER2 antibody, trastuzumab, in patients with recurrent or refractory ovarian or primary peritoneal carcinoma with overexpression of HER2: a phase II trial of the Gynecologic Oncology Group. J. Clin. Oncol. 21 2 (2003) 283-290
22. Farley J., Fuchiuji S., Darcy K.M., Tian C., Hoskins W.J., McGuire W.P., et al. Associations between ERBB2 amplification and progression-free survival and overall survival in advanced stage, suboptimally-resected epithelial ovarian cancers: a Gynecologic Oncology Group Study. Gynecol. Oncol. 113 3 (2009) 341-347
23. Tung K.H., Wilkens L.R., Wu A.H., McDuffie K., Nomura A.M., Kolonel L.N., et al. Effect of anovulation factors on pre- and postmenopausal ovarian cancer risk: revisiting the incessant ovulation hypothesis. Am. J. Epidemiol. 161 4 (2005) 321-329
24. Slotman B.J., Nauta J.J., and Rao B.R. Survival of patients with ovarian cancer. Apart from stage and grade, tumor progesterone receptor content is a prognostic indicator. Cancer 66 4 (1990) 740-744
25. Yang X.Y., Xi M.R., Yang K.X., and Yu H. Prognostic value of estrogen receptor and progesterone receptor status in young Chinese ovarian carcinoma patients. Gynecol. Oncol. 113 1 (2009) 99-104
26. Hatch K.D., Beecham J.B., Blessing J.A., and Creasman W.T. Responsiveness of patients with advanced ovarian carcinoma to tamoxifen. A Gynecologic Oncology Group study of second-line therapy in 105 patients. Cancer 68 2 (1991) 269-271
27. Rocereto T.F., Saul H.M., Aikins Jr. J.A., and Paulson J. Phase II study of mifepristone (RU486) in refractory ovarian cancer. Gynecol. Oncol. 77 3 (2000) 429-432
28. Smyth J.F., Gourley C., Walker G., MacKean M.J., Stevenson A., Williams A.R., et al. Antiestrogen therapy is active in selected ovarian cancer cases: the use of letrozole in estrogen receptor-positive patients. Clin. Cancer Res. 13 12 (2007) 3617-3622